CoChat
Sign Up
Cited by 328Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies

Open access
Mosconi, Lisa·2013·Clinical and Translational Imaging
DOI 10.1007/s40336-013-0026-yPMC PMC3881550
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder associated with progressive loss of cognitive function. 2-[18 F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has long been used to measure resting-state cerebral metabolic rates of glucose, a proxy for neuronal activity. Several FDG PET studies have shown that metabolic reductions occur decades before onset of AD symptoms, suggesting that metabolic deficits may be an upstream event in at least some late-onset AD cases. This review explores this possibility, initially discussing the link between AD pathology, neurodegeneration, oxidative stress and AD, and then discussing findings of FDG PET hypometabolism in AD patients as well as in at-risk individuals, especially those with a first-degree family history of late-onset AD. While the rare early-onset form of AD is due to autosomal dominant genetic mutations, the etiology and pathophysiology of age-dependent, late-onset AD is more complex. Recent FDG PET studies have shown that adult children of AD-affected mothers are more likely than those with AD-fathers to show AD-like brain changes. Given the connection between glucose metabolism and mitochondria, and the fact that mitochondrial DNA is maternally inherited in humans, it is here argued that altered bioenergetics may be an upstream event in those with a maternal history of late-onset AD. Biomarkers of AD have great potential for identifying AD endophenotypes in at-risk individuals, which may help direct investigation of potential susceptibility genes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40336-013-0026-y

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 105

  1. [3]Delacourte A David JP Sergeant N 1999 The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease Neurology 52 1158 1165 10214737
  2. [4]Price JL Ko AI Wade MJ Tsou SK McKeel DW Morris JC 2001 Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease Arch Neurol 58 1395 1402 11559310
  3. [7]Tanzi RE Bertram L 2001 New frontiers in Alzheimer’s disease genetics Neuron 32 181 184 11683989
  4. [8]Selkoe DJ 2002 Alzheimer’s disease is a synaptic failure Science 298 789 791 12399581
  5. [9]Selkoe DJ 1997 Alzheimer’s disease: genotypes, phenotypes, and treatments Science 275 630 631 9019820
  6. [12]Swerdlow RH 2012 Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer’s disease Antioxid Redox Signal 16 1434 1455 21902597 PMC3329949
  7. [13]Mattson MP Magnus T 2006 Ageing and neuronal vulnerability Nat Rev Neurosci 7 278 294 16552414 PMC3710114
  8. [15]Beal MF 1995 Aging, energy, and oxidative stress in neurodegenerative diseases Ann Neurol 38 357 366 7668820
  9. [16]Ames BN Shigenaga MK Hagen TM 1993 Oxidants, antioxidants, and the degenerative diseases of aging Proc Natl Acad Sci U S A 90 7915 7922 8367443 PMC47258
  10. [17]Terry RD Masliah E Salmon DP 1991 Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 30 572 580 1789684
  11. [18]Morrison JH Hof PR 1997 Life and death of neurons in the aging brain Science 278 412 419 9334292
  12. [19]Braak H Braak E Bohl J Reintjes R 1996 Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer’s disease Neurosci Lett 210 87 90 8783279
  13. [20]Sokoloff L 1977 Relation between physiological function and energy metabolism in the central nervous system J Neurochem 29 13 26 407330
  14. [21]Clarke DD Sokoloff L Siegel GJ Agranoff BW Albers RW Molinoff PB 1994 Circulation and energy metabolism of the brain Basic Neurochemistry New York Raven Press 645 680
  15. [22]Ray KK Seshasai SR Wijesuriya S 2009 Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 1765 1772 19465231
  16. [23]Wong-Riley MT 1989 Cytochrome oxidase: an endogenous metabolic marker for neuronal activity Trends Neurosci 12 94 101 2469224
  17. [25]Mecocci P MacGarvey U Beal MF 1994 Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease Ann Neurol 36 747 751 7979220
  18. [26]Subbarao KV Richardson JS Ang LC 1990 Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro J Neurochem 55 342 345 2355227
  19. [27]Kish SJ Bergeron C Rajput A 1992 Brain cytochrome oxidase in Alzheimer’s disease J Neurochem 59 776 779 1321237
  20. [29]Parker WD Jr Mahr NJ Filley CM 1994 Reduced platelet cytochrome c oxidase activity in Alzheimer’s disease Neurology 44 1086 1090 8208406
  21. [32]Reivich M Kuhl D Wolf A 1977 Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose Acta Neurol Scand Suppl 64 190 191 268783
  22. [34]Rocher AB Chapon F Blaizot X Baron JC Chavoix C 2003 Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons Neuroimage 20 1894 1898 14642499
  23. [35]Attwell D Iadecola C 2002 The neural basis of functional brain imaging signals Trends Neurosci 25 621 625 12446129
  24. [36]Mazziotta JC Phelps ME Phelps ME Mazziotta JC Schelbert H 1986 Positron emission tomography studies of the brain Positron Emission Tomography & Autoradiography: Principles & Applications for the Brain & Heart Raven Press New York 493 579
  25. [37]Phelps ME Huang SC Hoffman EJ Selin C Sokoloff L Kuhl DE 1979 Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method Ann Neurol 6 371 388 117743
  26. [38]Sokoloff L 1984 Modeling metabolic processes in the brain in vivo Ann Neurol 15 Suppl S1 11 6611107
  27. [39]Gjedde A Wienhard K Heiss WD 1985 Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant J Cereb Blood Flow Metab 5 163 178 3872872
  28. [40]Wienhard K Pawlik G Herholz K Wagner R Heiss WD 1985 Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures J Cereb Blood Flow Metab 5 115 125 3871780
  29. [41]Hutchins GD Holden JE Koeppe RA Halama JR Gatley SJ Nickles RJ 1984 Alternative approach to single-scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia J Cereb Blood Flow Metab 4 35 40 6607260
  30. [42]Lammertsma AA Brooks DJ Frackowiak RS 1987 Measurement of glucose utilisation with [18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods J Cereb Blood Flow Metab 7 161 172 3558499
  31. [43]Patlak CS Blasberg RG Fenstermacher JD 1983 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1 7 6822610
  32. [44]DiChiro G Brooks RA 1988 PET quantitation: blessing and curse J Nucl Med 29 1603 1604 3261788
  33. [45]Schmidt KC Lucignani G Sokoloff L 1996 Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination J Nucl Med 37 394 399 8667082
  34. [46]Drzezga A Grimmer T Riemenschneider M 2005 Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET J Nucl Med 46 1625 1632 16204712
  35. [47]Ishii K Willoch F Minoshima S 2001 Statistical brain mapping of 18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains J Nucl Med 42 548 557 11337540
  36. [48]Minoshima S Frey KA Koeppe RA Foster NL Kuhl DE 1995 A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET J Nucl Med 36 1238 1248 7790950
  37. [49]Minoshima S Giordani B Berent S Frey KA Foster NL Kuhl DE 1997 Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease Ann Neurol 42 85 94 9225689
  38. [50]Mosconi L Tsui WH Herholz K 2008 Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias J Nucl Med 49 390 398 18287270 PMC3703818
  39. [51]Herholz K Salmon E Perani D 2002 Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET Neuroimage 17 302 316 12482085
  40. [52]Caroli A Prestia A Chen K 2012 Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison J Nucl Med 53 592 600 22343502 PMC3640308
  41. [53]Prestia A Caroli A van der Flier WM 2013 Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease Neurology 80 1048 1056 23390179
  42. [54]Anchisi D Borroni B Franceschi M 2005 Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease Arch Neurol 11 62 1728 1733 16286547
  43. [55]Signorini M Paulesu E Friston K 1999 Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping Neuroimage 9 63 80 9918728
  44. [56]Teune LK Bartels AL de Jong BM 2010 Typical cerebral metabolic patterns in neurodegenerative brain diseases Mov Disord 25 2395 2404 20669302
  45. [57]Yakushev I Hammers A Fellgiebel A 2009 SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging Neuroimage 44 43 50 18691659
  46. [58]Wree A Schleicher A 1988 The determination of the local cerebral glucose utilization with the 2-deoxyglucose method Histochemistry 90 109 121 3068213
  47. [59]Hawkins RA Mans AM Davis DW Hibbard LS Lu DM 1983 Glucose availability to individual cerebral structures is correlated to glucose metabolism J Neurochem 40 1013 1018 6834033
  48. [60]Iadecola C Nakai M Mraovitch S Ruggiero DA Tucker LW Reis DJ 1983 Global increase in cerebral metabolism and blood flow produced by focal electrical stimulation of dorsal medullary reticular formation in rat Brain Res 272 101 114 6616188
  49. [61]Baron JC Lebrun-Grandie P Collard P Crouzel C Mestelan G Bousser MG 1982 Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication J Nucl Med 23 391 399 6978932
  50. [62]Raichle ME Grubb RL Jr Gado MH Eichling JO Ter-Pogossian MM 1976 Correlation between regional cerebral blood flow and oxidative metabolism. In vivo studies in man Arch Neurol 33 523 526 942309
  51. [63]Powers WJ Perlmutter JS Videen TO 1992 Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease Neurology 42 765 770 1565229
  52. [65]Sandman CA O’Halloran JP Isenhart R 1984 Is there an evoked vascular response? Science 224 1355 1357 6729458
  53. [66]Fox PT Raichle ME 1986 Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects Proc Natl Acad Sci U S A 83 1140 1144 3485282 PMC323027
  54. [67]Yarowsky P Kadekaro M Sokoloff L Frequency-dependent activation of glucose utilization in the superior cervical ganglion by electrical stimulation of cervical sympathetic trunk Proc Natl Acad Sci U S A 1983 80 4179 4183 6575402 PMC394224
  55. [68]Kadekaro M Vance WH Terrell ML Gary H Jr Eisenberg HM Sokoloff L 1987 Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat Proc Natl Acad Sci U S A 84 5492 5495 3474665 PMC298885
  56. [69]Zeki S Watson JD Lueck CJ Friston KJ Kennard C Frackowiak RS 1991 A direct demonstration of functional specialization in human visual cortex J Neurosci 11 641 649 2002358 PMC6575357
  57. [70]Petersen SE Fox PT Posner MI Mintun M Raichle ME 1988 Positron emission tomographic studies of the cortical anatomy of single-word processing Nature 331 585 589 3277066
  58. [71]Chugani HT Phelps ME Mazziotta JC 1987 Positron emission tomography study of human brain functional development Ann Neurol 22 487 497 3501693
  59. [72]Phelps ME Mazziotta JC 1985 Positron emission tomography: human brain function and biochemistry Science 228 799 809 2860723
  60. [73]Schubert D 2005 Glucose metabolism and Alzheimer’s disease Ageing Res Rev 4 240 257 15950548
  61. [74]Magistretti PJ Pellerin L 1999 Astrocytes couple synaptic activity to glucose utilization in the brain News Physiol Sci 14 177 182 11390847
  62. [75]Mosconi L 2005 Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD Eur J Nucl Med Mol Imaging 32 486 510 15747152
  63. [76]Silverman DH Small GW Chang CY 2001 Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome JAMA 286 2120 2127 11694153
  64. [77]Herholz K 2010 Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease Expert Rev Neurother 10 1667 1673 20977325
  65. [78]Caroli A Testa C Geroldi C 2007 Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment J Neurol 254 1000 1008 17375260
  66. [79]de Leon MJ Convit A Wolf OT 2001 Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci U S A 98 10966 10971 11526211 PMC58582
  67. [80]Mosconi L De Santi S Li J 2008 Hippocampal hypometabolism predicts cognitive decline from normal aging Neurobiol Aging 29 676 692 17222480 PMC2430185
  68. [81]Mosconi L Tsui W Murray J 2012 Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer’s disease Neurobiol Aging 33 624.e1 9 21514691 PMC3155000
  69. [82]Sun FT Schriber RA Greenia JM He J Gitcho A Jagust WJ 2007 Automated template-based PET region of interest analyses in the aging brain Neuroimage 34 608 617 17112749 PMC1828371
  70. [83]Mosconi L De Santi S Li Y 2006 Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET Eur J Nucl Med Mol Imaging 33 210 221 16311757
  71. [84]Drzezga A Becker JA Van Dijk KR 2011 Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden Brain 134 1635 1646 21490054 PMC3102239
  72. [85]Meguro K Blaizot X Kondoh Y Le Mestric C Baron JC Chavoix C 1999 Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer’s disease Brain 122 1519 1531 10430835
  73. [87]Morbelli S Piccardo A Villavecchia G 2010 Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study Eur J Nucl Med Mol Imaging 37 36 45 19662411
  74. [88]Mosconi L Tsui WH De Santi S 2005 Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis Neurology 64 1860 1867 15955934
  75. [89]Loessner A Alavi A Lewandrowski KU Mozley D Souder E Gur RE 1995 Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age J Nucl Med 36 1141 1149 7790936
  76. [90]Moeller JR Ishikawa T Dhawan V 1996 The metabolic topography of normal aging J Cereb Blood Flow Metab 16 385 398 8621743
  77. [93]Blass JP 2002 Alzheimer’s disease and Alzheimer’s dementia: distinct but overlapping entities Neurobiol Aging 23 1077 1084 12470805
  78. [94]Grady CL Haxby JV Schlageter NL Berg G Rapoport SI 1986 Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type Neurology 10 36 1390 1392 3762951
  79. [95]Haxby JV Grady CL Koss E 1990 Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type Arch Neurol 47 753 760 2357155
  80. [96]Fouquet M Desgranges B Landeau B 2009 Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer’s disease Brain 132 2058 2067 19477964 PMC2936690
  81. [97]Marshall GA Monserratt L Harwood D Mandelkern M Cummings JL Sultzer DL 2007 Positron emission tomography metabolic correlates of apathy in Alzheimer disease Arch Neurol 64 1015 1020 17620493
  82. [98]Kuczynski B Reed B Mungas D Weiner M Chui HC Jagust W 2008 Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease Arch Neurol 65 650 655 18474742 PMC2556212
  83. [99]Woo BK Harwood DG Melrose RJ 2010 Executive deficits and regional brain metabolism in Alzheimer’s disease Int J Geriatr Psychiatry 25 1150 1158 20069587
  84. [101]Jagust W Gitcho A Sun F Kuczynski B Mungas D Haan M 2006 Brain imaging evidence of preclinical Alzheimer’s disease in normal aging Ann Neurol 59 673 681 16470518
  85. [102]Mosconi L Mistur R Switalski R 2009 FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease Eur J Nucl Med Mol Imaging 36 811 822 19142633 PMC2774795
  86. [103]Mosconi L Sorbi S de Leon MJ 2006 Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease J Nucl Med 47 1778 1786 17079810
  87. [104]Nobili F De Carli F Frisoni GB 2009 SPECT predictors of cognitive decline and Alzheimer’s disease in mild cognitive impairment J Alzheimers Dis 17 761 772 19542623
  88. [105]Chetelat G Desgranges B de la Sayette V Viader F Eustache F Baron JC 2003 Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60 1374 1377 12707450
  89. [106]Drzezga A Lautenschlager N Siebner H 2003 Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study Eur J Nucl Med Mol Imaging 30 1104 1113 12764551
  90. [107]Valla J Berndt JD Gonzalez-Lima F 2001 Energy hypometabolism in posterior cingulate cortex of Alzheimer’s patients: superficial laminar cytochrome oxidase associated with disease duration J Neurosci 21 4923 4930 11425920 PMC6762373
  91. [108]Liang WS Reiman EM Valla J 2008 Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons Proc Natl Acad Sci U S A 105 4441 4446 18332434 PMC2393743
  92. [109]Reiman EM Caselli RJ Chen K Alexander GE Bandy D Frost J 2001 Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease Proc Natl Acad Sci U S A 98 3334 3339 11248079 PMC30654
  93. [110]Reiman EM Chen K Alexander GE 2004 Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia Proc Natl Acad Sci U S A 101 284 289 14688411 PMC314177
  94. [111]Reiman EM Chen K Alexander GE 2005 Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism Proc Natl Acad Sci U S A 102 8299 8302 15932949 PMC1149416
  95. [112]Farrer LA O’Sullivan DM Cupples LA Growdon JH Myers RH 1989 Assessment of genetic risk for Alzheimer’s disease among first-degree relatives Ann Neurol 25 485 493 2774490
  96. [114]Mosconi L Brys M Switalski R 2007 Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism Proc Natl Acad Sci U S A 104 19067 19072 18003925 PMC2141909
  97. [115]Mosconi L Mistur R Switalski R 2009 Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease Neurology 72 513 520 19005175 PMC2677512
  98. [116]Wilding M Di Matteo L Dale B 2005 The maternal age effect: a hypothesis based on oxidative phosphorylation Zygote 13 317 323 16388700
  99. [120]Berti V Mosconi L Glodzik L 2011 Structural brain changes in normal individuals with a maternal history of Alzheimer’s Neurobiol Aging 32 2325.e17 26 21316814 PMC3115436
  100. [122]Honea RA Swerdlow RH Vidoni ED Goodwin J Burns JM 2010 Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease Neurology 74 113 120 20065246 PMC2809030
  101. [123]Andrawis JP Hwang KS Green AE 2012 Effects of ApoE4 and maternal history of dementia on hippocampal atrophy Neurobiol Aging 33 856 866 20833446 PMC3010297
  102. [124]Klunk WE Engler H Nordberg A 2004 Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol 55 306 319 14991808
  103. [125]Mosconi L Rinne JO Tsui WH 2010 Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer’s Proc Natl Acad Sci U S A 107 5949 5954 20231448 PMC2851906
  104. [126]Mosconi L Rinne JO Tsui WH 2013 Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer’s parents Neurobiol Aging 34 22 34 22503001 PMC3402654
  105. [127]Mosconi L Andrews R Matthews DC 2013 Comparing brain amyloid deposition, glucose metabolism and atrophy in mild cognitive impairment with and without a family history of dementia J Alzheimer’s Dis 35 509 524 23478305

Cited by

Sorted by citations

Authors
Mosconi, L.
Affiliations
NYU Langone Health (US)
Corresponding author
Mosconi, Lisa
ORCID
Mosconi, Lisa
Venue
Clinical and Translational Imaging
Publisher
Springer Science and Business Media LLC
Published
2013-07-10
Volume
1
Issue
4
Pages
217-233
ISSN
  • 2281-5872 (ISSN-L)
  • 2281-7565
DOI
10.1007/s40336-013-0026-y
PMC
PMC3881550
OpenAlex
W2009487160
Cited by
328
References
21
Citations by year
2026: 27 · 2025: 34 · 2024: 27 · 2023: 21 · 2022: 51 · 2021: 32 · 2020: 32 · 2019: 22 · 2018: 31 · 2017: 19 · 2016: 13 · 2015: 8 · 2014: 8 · 2013: 1
FWCI
6.50
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Clinical and Translational Imaging (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Alzheimer's Association (IIRG-09-132030)
  • National Institutes of Health
  • National Institute on Aging (AG035137, AG032554, R21AG032554, R01AG013616, R01AG035137, AG 13616)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, glucose metabolism, FDG-PET, cerebral metabolic rate of glucose, normal aging, neurodegeneration, oxidative stress, early-onset Alzheimer's disease, late-onset Alzheimer's disease, family history of Alzheimer's disease, maternal inheritance, mitochondrial DNA, bioenergetics, biomarkers, endophenotypes, susceptibility genes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review